Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is based upon the following points:

1. Resistance to trastuzumab, either primary or secondary, is a clinically relevant issue.
2. PI3K/AKT activation, due to loss of expression/function of PTEN and/or activating mutations of PIK3CA, is a mechanism of resistance with clinical relevance in breast cancer. Such activation can be detected by:

* IHC evaluation of PTEN protein expression
* genotyping of PIK3CA exon 9 and 20
* IHC evaluation of phospho-AKT expression
3. BKM120 is an effective PI3K inhibitor. BKM120 and anti-HER2 therapy may have a synergistic antitumor activity in preclinical model of HER2+ breast cancer.
4. Lapatinib is an effective anti-HER2 therapy in trastuzumab-resistant disease.
5. For the evaluation of novel targeted therapies, selecting a patient population enriched for activation of the target to be modulated should allow to maximize the differences in clinical outcome that are expected in the experimental arm, and thus to minimize the patient number to include.
6. We propose to test in a phase I/II study the combination of lapatinib and BKM120 in trastuzumab-resistant HER2+ MBC patients, enriched for activation of PI3K/AKT as detected by loss of expression of PTEN (IHC), and/or mutation of PIK3CA and/or overexpression of phospho-AKT (IHC). Only for phase II patients, mutational status will be an inclusion criteria. For phase I patients molecular status will be a retrospective exploratory analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

NCT01572727

Breast Cancer

COMPLETED PHASE2/PHASE3

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

NCT01633060

Metastatic Breast Cancer

TERMINATED PHASE3

Pharmacodynamic Study of BKM120 in Breast Cancer

NCT01513356

Breast Cancer

COMPLETED EARLY_PHASE1

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

NCT00356811

Neoplasms, Breast

COMPLETED PHASE2

Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer

NCT01980277

Breast Cancer

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BKM120+Lapatinib

BKM120 40, 60 or 80 mg/day per os for 28 days cycle

\+ Lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle

Group Type EXPERIMENTAL

BKM120 + lapatinib

Intervention Type DRUG

BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BKM120 + lapatinib

BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BKM120 and lapatinib

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female or male ≥ 18 years
2. WHO performance status ≤ 1
3. Locally advanced, recurrent or metastatic, histologically confirmed HER2 positive (IHC 3+ or FISH positive) breast cancer after failure of trastuzumab treatment.

while on trastuzumab or within 4 weeks since the last infusion of trastuzumab for metastatic disease within 12 months of the last infusion for patients who received trastuzumab as adjuvant or neoadjuvant treatment
4. For the phase II part, progression on trastuzumab must have occurred within 16 weeks before entering this trial.
5. should not have received more than 3 lines of anti-HER2 therapy.
6. For the phase II part, activation of PI3K/AKT pathway
7. capable of understanding the protocol and has signed the informed consent
8. laboratory values within normal range
9. Measurable disease
10. Patients may have received treatment for brain metastases, but must be neurologically stable
11. Baseline LVEF\>50% (MUGA or ECHO)
12. Affiliation to social security

Exclusion Criteria

1. Previous treatment with lapatinib, neratinib or a PI3K inhibitor
2. untreated brain metastases.
3. acute or chronic liver, renal disease or pancreatitis
4. any peripheral neuropathy ≥ CTCAE grade 2
5. any of the following mood disorders, or meets the cut-off score of ≥ 10 in the PHQ-9 or a cut-off of ≥ 15 in the GAD-7 mood scale, respectively, or selects a positive response of '1, 2, or 3' to question number 9 regarding potential for suicidal thoughts ideation in the PHQ-9 (independent of the total score of the PHQ-9)

* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
* ≥ CTCAE grade 3 anxiety
6. diarrhea ≥ CTCAE grade 2
7. active cardiac disease
8. history of cardiac dysfunction
9. poorly controlled diabetes mellitus (HbA1c \> 8 %)
10. Other severe and/or uncontrolled concomitant medical conditions
11. Impairment of gastrointestinal function that may significantly alter the absorption of BKM120
12. been treated with any hematopoietic colony-stimulating growth factors ≤ 2 weeks prior to starting study drug.
13. currently receiving treatment with medication with a known risk prolong the QT interval or inducing Torsades de Pointes
14. currently being treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A
15. receiving chronic treatment with steroids or another immunosuppressive agent.
16. have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies \[other than trastuzumab\] or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
17. have received small molecule therapeutics (excluding monoclonal antibodies) ≤ 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy
18. have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
19. have undergone major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy
20. Known diagnosis of HIV infection
21. History of another malignancy within 3 years
22. Patient is unable or unwilling to abide by the study protocol
23. pregnant or breast feeding women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No